Trunate-60
Protect The Developing Nexus Of Type 2 DM


Composition : Nateglinide 60mg

Form : Tablets / Pack : 10 x 10’s / Type : ALU-ALU

Description : This randomized double-blind placebo-controlled multicenter study was conducted in 289 patients who received either nateglinide at doses of 30 mg (n = 51), 60 mg (n = 58), 120 mg (n = 63), or 180 mg (n = 57) or placebo (n = 60) before three main meals for 12 weeks. Levels of HbA1c, fasting plasma glucose (FPG), fructosamine, and plasma lipids were measured at predetermined intervals, and the effects of nateglinide on prandial glucose insulin, C-peptide, and triglyceride levels were measured after a liquid standard meal (Sustacal; Mead Johnson, Evansville, IN). Adverse events and hypoglycemic episodes were recorded.
RESULTS: After a liquid meal challenge, nateglinide rapidly increased mealtime insulin levels within 30 min of drug intake and reduced mealtime glucose excursions without affecting triglyceride levels. At study end point, reduction of HbA1c levels was statistically significantly greater with nateglinide at doses of 60, 120, and 180 mg than placebo (-0.45, -0.62, and -0.64%, respectively; P<0.05). The mean level of FPG was significantly reduced versus placebo in the nateglinide 120-mg group only (-1.14 mmol/l P<0.01). Overall, nateglinide was well tolerated.
CONCLUSIONS: This study demonstrated that nateglinide improves mealtime and mean glycemic control in a dose-dependent manner by restoring early insulin secretion phase. Nateglinide was well tolerated and is suitable for the treatment of patients with type 2 diabetes- Diabetes Care 2000 Feb; 23(2): 202-207.

View more products with following salts

Repa X-2
So Sweet Sir…. Need Not Sweets


Composition : Repaglinide 2mg

Form : Tablets / Pack : 10 x 10’s / Type : ALU-ALU

Description : This multinational, open-label study comprised a 6-week run-in period, continuing prestudy antidiabetic medication, followed by a titration period (1–4 weeks) and a 3-month maintenance period. Patients with normal renal function (n = 151) and various degrees of renal impairment (n = 130) were treated with repaglinide (maximal dose of 4 mg, three times daily). Safety and efficacy assessments were performed at baseline (end of run-in) and at the end of study treatment.
RESULTS: The type and severity of adverse events during repaglinide treatment were similar to the run-in period. The number of patients with adverse events was not significantly related to renal function during run-in or repaglinide treatment. Percentage of patients with hypoglycemic episodes increased significantly (P = 0.007) with increasing severity of renal impairment during run-in but not during repaglinide treatment (P = 0.074). Metabolic control (HbA1c and fasting blood glucose) with repaglinide was unchanged from that on previous antidiabetic medication. Final repaglinide dose tended to be lower for patients with severe and extreme renal impairment than for patients with less severe renal impairment or normal renal function (P = 0.032).
CONCLUSIONS: Repaglinide has a good safety and efficacy profile in type 2 diabetic patients complicated by renal impairment and is an appropriate treatment choice, even for individuals with more severe degrees of renal impairment- Diabetes Care 2003 Mar; 26(3): 886-891.

View more products with following salts

Repa X-1
So Sweet Sir…. Need Not Sweets


Composition : Repaglinide 1mg

Form : Tablets / Pack : 10 x 10’s / Type : ALU-ALU

Description : This multinational, open-label study comprised a 6-week run-in period, continuing prestudy antidiabetic medication, followed by a titration period (1–4 weeks) and a 3-month maintenance period. Patients with normal renal function (n = 151) and various degrees of renal impairment (n = 130) were treated with repaglinide (maximal dose of 4 mg, three times daily). Safety and efficacy assessments were performed at baseline (end of run-in) and at the end of study treatment.
RESULTS: The type and severity of adverse events during repaglinide treatment were similar to the run-in period. The number of patients with adverse events was not significantly related to renal function during run-in or repaglinide treatment. Percentage of patients with hypoglycemic episodes increased significantly (P = 0.007) with increasing severity of renal impairment during run-in but not during repaglinide treatment (P = 0.074). Metabolic control (HbA1c and fasting blood glucose) with repaglinide was unchanged from that on previous antidiabetic medication. Final repaglinide dose tended to be lower for patients with severe and extreme renal impairment than for patients with less severe renal impairment or normal renal function (P = 0.032).
CONCLUSIONS: Repaglinide has a good safety and efficacy profile in type 2 diabetic patients complicated by renal impairment and is an appropriate treatment choice, even for individuals with more severe degrees of renal impairment- Diabetes Care 2003 Mar; 26(3): 886-891.

View more products with following salts

Repa X-0.5
So Sweet Sir…. Need Not Sweets


Composition : Repaglinide 0.5mg

Form : Tablets / Pack : 10 x 10’s / Type : ALU-ALU

Description : This multinational, open-label study comprised a 6-week run-in period, continuing prestudy antidiabetic medication, followed by a titration period (1–4 weeks) and a 3-month maintenance period. Patients with normal renal function (n = 151) and various degrees of renal impairment (n = 130) were treated with repaglinide (maximal dose of 4 mg, three times daily). Safety and efficacy assessments were performed at baseline (end of run-in) and at the end of study treatment.
RESULTS: The type and severity of adverse events during repaglinide treatment were similar to the run-in period. The number of patients with adverse events was not significantly related to renal function during run-in or repaglinide treatment. Percentage of patients with hypoglycemic episodes increased significantly (P = 0.007) with increasing severity of renal impairment during run-in but not during repaglinide treatment (P = 0.074). Metabolic control (HbA1c and fasting blood glucose) with repaglinide was unchanged from that on previous antidiabetic medication. Final repaglinide dose tended to be lower for patients with severe and extreme renal impairment than for patients with less severe renal impairment or normal renal function (P = 0.032).
CONCLUSIONS: Repaglinide has a good safety and efficacy profile in type 2 diabetic patients complicated by renal impairment and is an appropriate treatment choice, even for individuals with more severe degrees of renal impairment- Diabetes Care 2003 Mar; 26(3): 886-891.

View more products with following salts

Repamet-0.5
So Sweet Sir…. Need Not Sweets


Composition : Repaglinide 0.5mg + Metformin 500 mg SR

Form : Tablets / Pack : 10 x 10’s / Type : Blister

Description : Repaglinide is a rapidly absorbed, short-acting insulin secretagogue targeting postprandial glucose excursions; metformin is an insulin sensitizer with a longer duration of action that principally regulates basal glucose levels. A pivotal, 26-week, randomized study with repaglinide/metformin FDC therapy has been conducted in patients experiencing suboptimal control with previous oral antidiabetes therapy. Repaglinide/metformin FDC improved glycemic control and weight neutrality without adverse effects on lipid profiles. There were no major hypoglycemic episodes and patients expressed greater satisfaction with repaglinide/metformin FDC than previous treatments. Repaglinide/metformin FDC is expected to be more convenient than individual tablets for patients taking repaglinide and metformin in loose combination, and it is expected to improve glycemic control in patients for whom meglitinide or metformin monotherapies provide inadequate control- Diabetes Metab Syndr Obes. 2010; 3: 145–154

View more products with following salts

Repamet-1
So Sweet Sir…. Need Not Sweets


Composition : Repaglinide 1mg + Metformin 500 mg SR

Form : Tablets / Pack : 10 x 10’s / Type : Blister

Description : Repaglinide is a rapidly absorbed, short-acting insulin secretagogue targeting postprandial glucose excursions; metformin is an insulin sensitizer with a longer duration of action that principally regulates basal glucose levels. A pivotal, 26-week, randomized study with repaglinide/metformin FDC therapy has been conducted in patients experiencing suboptimal control with previous oral antidiabetes therapy. Repaglinide/metformin FDC improved glycemic control and weight neutrality without adverse effects on lipid profiles. There were no major hypoglycemic episodes and patients expressed greater satisfaction with repaglinide/metformin FDC than previous treatments. Repaglinide/metformin FDC is expected to be more convenient than individual tablets for patients taking repaglinide and metformin in loose combination, and it is expected to improve glycemic control in patients for whom meglitinide or metformin monotherapies provide inadequate control- Diabetes Metab Syndr Obes. 2010; 3: 145–154.

View more products with following salts

Tinage-20
The most studied DPP4i


Composition : Teneligliptin 20mg

Form : Tablets / Pack : 10’s / Type : ALU-ALU

Description : Unique structure (*Anchor lock domain* - S2 extensive binding). High selectivity and tight binding (5 fold) for DPPi4 Longer half life (t1/2: ~24 hours) Less chances of food-drug and drug-drug interactions, Proven efficacy as mono as well as combination therapy. Effective glycemic control. Duel route of excretion so effective in patients of renal impairment.

View more products with following salts

Repamet – 2
So Sweet Sir…. Need Not Sweets


Composition : Repaglinide 2mg + Metformin 500 mg

Form : Tablets / Pack : 10’s / Type : ALU-ALU

Description : An FDC tablet of repaglinide/metform 2 mg/500 was bioequvalent to individual tablets of repalinide 2 mg and metformin 500 mg. Additionally, an FDC tablet of repeglinide/metformin 2 mg/500 mg Finally, no unexpected safety convern were noted with repaglinide/metformin combination tablet therapy. Our results suggest that FDC tablets of repaglinide and metformin would provide safety and efficacy comparable to that of repaglinide and metformin administered as separate formulations - Clin Drug Investig. 2008; 28(9): 573-82. Repaglinide Stimulates Release Of Insulin From Pancreatic B-Cells By Inhibiting K Efflux Via Closure Of ATP Regulated K Channels, This Results In Depolarization Of The Cell and Opening of Voltage-Dependent Ca Channels, Which Increases Influx Of Ca Into The Beta Cells And Causes Release of Insulin

View more products with following salts